What is the fair value of GILD stock?

Our analysis estimates the fair value range for GILD to be between $128.83 and $134.30. The current price is $133.21.

What is the analyst price target for GILD?

The average Wall Street analyst price target for GILD is $157.41. This implies a potential upside of 18.2% from current levels.

GILD Stock Analysis: Buy, Sell, or Hold?

GILD - Gilead Sciences Inc

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

$133.21

2.35 (1.80%) ▲

5d: +2.3%

30d: -1.21%

90d: -0.63%

WAIT

LOW Confidence

Protect Your GILD Gains

Analysis Updated: Aug 7, 2026 12:00 AM ET

Earnings: Aug 04, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 7, 2026 at $133.21 · last confirmed Aug 7, 2026

Strength: 6.0/10

Get Alerted When GILD Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
ℹ️ NEUTRAL: GILD is fairly priced but lacks strong directional signals. At -1.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 10.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$197.85

Based on 7.0% avg growth

INTRINSIC VALUE TODAY

$122.85

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: GILD is currently trading at $133.21, which is considered slightly high relative to its 30-day fair value range of $128.83 to $134.30. The stock's valuation (Forward PE: 13.5) is in line with its historical norms (14.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This pessimistic expectation contrasts with the company's recent 54.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, GILD is in a uptrend. Immediate support is located at $128.28, while resistance sits at $137.80.

Market Sentiment: The stock shows a mixed technical setup (54/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $157.41 (+18.2%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH

Historical Trading Range $128.83 - $134.30

Company Quality Score 53/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 62.9%

Protect Your Profits

Holding GILD? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

NEUTRAL: Mixed technical signals (54/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($157.41)
WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $128.83 - $134.30

Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $128.28

Resistance Level $137.80

Current Trend Uptrend

Technical data as of Aug 7, 2026

Fundamental Context

Forward P/E (Next Year Est.) 13.49

Wall Street Target $157.41 (+18.2%)

Revenue Growth (YoY) 10.2%

Earnings Growth (YoY) 54.8%

Profit Margin -10.6%

Valuation Discount vs History -1.8% cheaper

PE vs Historical 13.5 vs 14.3 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -1.8% (market-implied from PE analysis)

1-Year Target $130.81 (-2%)

2-Year Target $128.46 (-4%)

3-Year Target $126.15 (-5%)

3-Yr Target (if PE normalizes) (PE: 13→14) $133.71 (+0%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (13x PE) as earnings recover.

Trailing PE: 18.43 | Current EPS (TTM): $7.34

Bull Case $194.96 (+48%)

Analyst growth 31.0%, PE expands to 20.3

Base Case $177.23 (+35%)

Market implied 31.0%, PE stable at 18.4

Bear Case $91.97 (-30%)

Severe decline -20.0%, PE contracts to 15.7

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 13.5 to 14.3

Stabilization Target: $141.20 (+6.0%)

PE Expansion Potential: +6.0%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 08, 2026 5:59 PM ET
Data refreshes hourly during market hours. Next update: 6:59 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is GILD showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Andrew D Dickinson SELL 3000 shares 2026-04-15

Johanna Mercier SELL 3000 shares 2026-04-15

Andrew D Dickinson SELL 3000 shares 2026-03-16

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for GILD.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1277	49 HOLD
ABBV AbbVie Inc	BUY 28 analysts	$270	53 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$234	53 HOLD
MRK Merck & Company Inc	BUY 26 analysts	$135	51 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$357	36 SELL

LLY Eli Lilly and Com…

MRK Merck & Company I…

51 HOLD

AMGN Amgen Inc

36 SELL

Advanced GILD Option Strategies

Professional options setups generated by AI based on today's GILD price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for GILD

GILD Technical Chart GILD Price Prediction GILD Earnings Date GILD Investment Advisor GILD Fair Price Analyzer GILD Options Advisor GILD Options Chain GILD Options Analysis GILD Competitors

Compare GILD with Peers

GILD vs AMGN
Which one to buy?

GILD vs BIIB
Which one to buy?

GILD vs ABBV
Which one to buy?

GILD vs BMY
Which one to buy?

GILD vs REGN
Which one to buy?

KLRS vs GILD
Winner: GILD

Create New Comparison View All Competitors

Tradestie